ReNeuron Group plc:
Clin-stage, UK-based cell therapy; allogeneic, off-the-shelf candidates: chronic stroke disability (Ph3 design approved by FDA); retinitis pigmentosa (Ph1/2 ongoing), cone rod dystrophy (Ph2 initiation); PC exosome nanomedicine platform program, first indication GMBM. GMP commercial scale cell production capability.
10 Nugent Road
Surrey Research Park
Guilford, GU2 7AF
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by